Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT07107945 |
| Consolidated Lead Sponsor | Boehringer Ingelheim |
| Therapeutic Condition Cohort | Gastroenterology, Hepatology, and Renal |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 135 participants (ACTUAL) |
| Registered Start Date | 2025-12-09 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| University of Alabama at Birmingham | Birmingham, AL | Open Hospital Dossier -> |
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | Open Hospital Dossier -> |
| UC Davis Comprehensive Cancer Center | Sacramento, CA | Open Hospital Dossier -> |
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.